Please wait while the formulary information is being retrieved.
ZYPITAMAG (pitavastatin magnesium)
- Hypercholesterolemia
- Hyperlipidemia
- Mixed hyperlipidemia
1 mg tablet
- 1 tablet (1 mg) by oral route once daily
2 mg tablet
- 1 tablet (2 mg) by oral route once daily
4 mg tablet
- 1 tablet (4 mg) by oral route once daily
Hypercholesterolemia
- 1 tablet (1 mg) by oral route once daily
- 2 tablets (2 mg) by oral route once daily
- 1 tablet (2 mg) by oral route once daily
- 2 tablets (4 mg) by oral route once daily
- 1 tablet (4 mg) by oral route once daily
Hyperlipidemia
- 1 tablet (1 mg) by oral route once daily
- 2 tablets (2 mg) by oral route once daily
- 1 tablet (2 mg) by oral route once daily
- 2 tablets (4 mg) by oral route once daily
- 1 tablet (4 mg) by oral route once daily
Mixed hyperlipidemia
- 1 tablet (1 mg) by oral route once daily
- 2 tablets (2 mg) by oral route once daily
- 1 tablet (2 mg) by oral route once daily
- 2 tablets (4 mg) by oral route once daily
- 1 tablet (4 mg) by oral route once daily
- cyclosporine
- cyclosporine modified
- Erythrocin
- erythromycin
- erythromycin-sulfisoxazole
- Gengraf
- isoniazid-rifamp-pyrazinamide
- Neoral
- Rifadin
- Rifamate
- rifampin
- rifampin-isoniazid
- Rifater
- Sandimmune
Contraindicated
- Antara
- Cubicin
- daptomycin
- Endur-acin
- fenofibrate
- fenofibrate micronized
- fenofibrate nanocrystallized
- fenofibric acid
- fenofibric acid (choline)
- Fenoglide
- Fibricor
- Lipofen
- Lofibra
- niacin
- niacin (inositol niacinate)
- niacinamide
- Niacor
- Niaspan Extended-release
- Slo-niacin
- Tricor
- Triglide
- Trilipix
Severe
Moderate
- amoxicil-clarithromy-lansopraz
- Biaxin
- Biaxin Xl
- Biaxin Xl Pak
- clarithromycin
- colchicine
- colchicine-probenecid
- Colcrys
- Omeclamox-pak
- omeprazole-clarith-amoxicillin
- Prevpac
- Disease of liver
- Lactating mother
- Pregnancy
- Rhabdomyolysis
Contraindicated
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Dehydration
- Immune-mediated necrotizing myopathy
- Intracerebral hemorrhage
- Invasive surgical procedure
- Major traumatic injury
- Myopathy with CK elevation
- Sepsis
- Severe hypotension
- Uncontrolled epilepsy
Severe
Moderate
- Hyperglycemia
- Memory impairment
- Metabolic syndrome X
- Untreated hypothyroidism
ZYPITAMAG (pitavastatin magnesium)
- Hypercholesterolemia
- Hyperlipidemia
- Mixed hyperlipidemia
- None
- Back pain
- Constipation
- Diarrhea
- Limb pain
- Myalgias
- Pain
More Frequent
Severe
Less Severe
- None
- Arthralgias
- Headache disorder
- Influenza
- Pharyngitis
- Skin rash
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Angioedema
- Hepatic failure
- Hepatitis
- Immune-mediated necrotizing myopathy
- Interstitial lung disease
- Jaundice
- Myopathy
- Rhabdomyolysis
- Urticaria
Less Severe
- Acute abdominal pain
- Acute confusion
- Depression
- Dizziness
- Dyspepsia
- Erectile dysfunction
- Fatigue
- General weakness
- Hyperglycemia
- Hypesthesia
- Insomnia
- Malaise
- Memory impairment
- Muscle spasm
- Nausea
- Peripheral neuropathy
- Pruritus of skin
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Pitavastatin
Study demonstrated efficacy in age > 6 years. Manufacturer states safety and efficacy not established in age < 8 years.
- 1 Day – 8 Years
- Study demonstrated efficacy in age > 6 years. Manufacturer states safety and efficacy not established in age < 8 years.
Pitavastatin
- Severity Level:
1
- Additional Notes: Theoretical risk based on drug mechanism of action
Contraindicated
Pitavastatin
Other similar drugs excreted into breast milk; caution advised
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Other similar drugs excreted into breast milk; caution advised |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Pitavastatin
Renal- Adjust starting dose and do not exceed a maximum of 2 mg/day for CrCL<60 mL/min. Hepatic-Monitor hepatic transaminases. Musculoskeletal-Elderly patients greater than age 65 may be at increased risk for myopathy and rhabdomyolysis. Rhabdomyolysis and myopathy risk is greatest when starting or increasing dose. Gastrointestinal-Constipation risk. In clinical trials, approximately 2% of patients experienced constipation.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Hypercholesterolemia | |
| E78.0 | Pure hypercholesterolemia |
| E78.00 | Pure hypercholesterolemia, unspecified |
| E78.01 | Familial hypercholesterolemia |
| Hyperlipidemia | |
| E78.2 | Mixed hyperlipidemia |
| E78.4 | Other hyperlipidemia |
| E78.49 | Other hyperlipidemia |
| E78.5 | Hyperlipidemia, unspecified |
| Mixed hyperlipidemia | |
| E78.2 | Mixed hyperlipidemia |
| 0-9 | A-Z |
|---|---|
| E78.0 | Pure hypercholesterolemia |
| E78.00 | Pure hypercholesterolemia, unspecified |
| E78.01 | Familial hypercholesterolemia |
| E78.2 | Mixed hyperlipidemia |
| E78.2 | Mixed hyperlipidemia |
| E78.4 | Other hyperlipidemia |
| E78.49 | Other hyperlipidemia |
| E78.5 | Hyperlipidemia, unspecified |
Formulary Reference Tool